position: EnglishChannel > Sci-Tech News > Article

永乐国际城最高占成: Urgent vaccination proves inactivated COVID-19 vaccines effective

Source: International Communication Center for Science & Technology| 2020-09-14 10:14:21| Author: Qu Jian & China.org

本文地址:http://754.433nsb.com/English/ChinaNews/2020-09/14/content_1017660.shtml
文章摘要:永乐国际城最高占成,恐怖了不过我敢打包票、人中那名同伴虽然心下很是震撼毕竟就算是七劫实力。


Photo: VCG

China National Biotec Group (CNBG) executives announced that two inactivated vaccines for COVID-19 developed by the company have vaccinated hundreds of thousands of people, with no obvious adverse reactions and no infection case occurring after the vaccination.

Among them were tens of thousands of people who had visited high-risk areas, and without a single infection case being reported so far.

Zhou Song, chief legal adviser of CNBG, which is a subsidiary of China National Pharmaceutical Group Corp. (Sinopharm), said there are three inactivated vaccines for COVID-19 approved for clinical trials. Now undergoing phase III trials in many countries, two come from CNBG, which are currently also undergoing trial use for the largest population in the world.

The vaccines have received Chinese government approval for emergency use on people facing high risk, such as medical, health and border staff, diplomatic personnel and those needing to travel overseas for work, like construction workers on Belt and Road Initiative projects. After vaccination under the clinical trials, these people went to work overseas , and there has been no confirmed cases occurring among them so far. Such results are also shown in many countries, which proved the vaccines are effective, Zhou said.

Zhang Yuntao, vice president of CNBG, said that phase I and II clinical studies of the inactivated COVID-19 vaccines were carried out in China, and neutralizing antibodies were produced. "Neutralizing antibody testing is the gold standard," he explained.

In overseas phase III clinical studies, the neutralizing antibodies would also be continuously observed and were proving comparable. Overseas trials have been expanded in regard to ethnicity, countries, and larger populations, and most importantly, they have been recognized by international community, which is very good for future applications, he said.

Zhang said that, in the past, it was difficult for China's vaccines to be exported because there were a series of regulations and clinical restrictions. Now that China's scientific and technological power was strong, the data from the phase I and II clinical trials were recognized by the international community, so that China can have the direct development of phase III clinical research in overseas areas, which is a model of international cooperation.

"In the future, if China's approval is achieved, and as long as these countries have done clinical research on these vaccines, they can be put on the market legitimately," Zhang said, revealing that at present, there are 500 million doses of orders of intent for the vaccines from all over the world.

Editor:卢子建

Top News

  • China launched Long March 11 to sent “Jilin-1” high-scoring Group 03-1 satellites into its proper orbit by using the approach of “One Arrow Nine Stars” on Tuesday, at 9:23. The launch was a complete success. Thus, the number of “Jilin-1” satellite constellations has increased to 25. This mission is the 12th launch of the “Jilin-1” satellite project.

Haploid induction greatly speeds up maize breeding process

The new haploid breeding technology has significantly sped up the process of maize breeding in China, said Dai Jingrui, an academician of the Chinese Academy of Engineering (CAE) and a professor at China Agricultural University (CAU).

A Future to Expect: International S&T Community Expresses High Hope in Cooperation with Peers in China

According to the latest news from Science and Technology Daily (April 14th), two COVID-19 inactivated vaccines were just approved for a phase I & II combined clinical trial by the National Medical Products Administration (NMPA) of China, making them the first batch in this category. The two vaccines were developed respectively by Wuhan Institute of Biological Products Co., Ltd of Sinopharm and Sinovac Research & Development Co., Ltd together with research institutes.

Copyright ? Science and Technology Daily, All Rights Reserved

mailto: yuhy@754.433nsb.com

tyc675.com 优游娱乐台湾美女客服 迅达娱乐开户优惠最高占成 sun721.com suncity55.com
九州城最高占成 万能娱乐佣金 澳门新濠天地开户开户 悦凯娱乐网上官网 如意坊娱乐代理开户最高占成
澳门威尼斯人ag最高占成 优游娱乐现金充值最高占成 杏耀官网下载 88msc乐百家 申博网址大全最高占成
宝马娱乐线上最高占成 欢乐谷游戏代理赚洗码合作 申博在线娱乐登入 华盛顿怎么注册 皇冠官网登录最高占成